DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A phase 2 trial of Palbociclib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Criterium, Inc., active and no longer recruiting.
Overview
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) is a phase 2 interventional study registered as NCT04567420 by Criterium, Inc., with 70 participants enrolled, started 2021-02-09 and due to reach its primary completion in 2027-12-31. Interventions recorded: Palbociclib, Fulvestrant and Adjuvant Therapy.
Similar pages
not linked directly; found by shared links- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Shares Palbociclib, Fulvestrant and the tag pipeline.
- TrialEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.